MYOT (Myotilin) is a gene encoding a Z-disc protein critical for sarcomere organization and maintenance. Mutations in MYOT cause myofibrillar myopathy (MFM), a heterogeneous group of disorders characterized by focal disruption of myofibrils and accumulation of desmin, myotilin, and other proteins into inclusion bodies. While primarily considered a neuromuscular disease gene, MYOT has implications for understanding protein aggregation and cellular stress responses relevant to neurodegenerative diseases[@selcen2004].
The MYOT gene is located on chromosome 19q13.33, comprising 13 exons that encode a protein of 493 amino acids. The gene spans approximately 11.5 kilobases of genomic DNA. The promoter region contains binding sites for multiple transcription factors, including MEF2 and myoD, consistent with muscle-specific expression.
MYOT (Myotilin) is a gene encoding a Z-disc protein critical for sarcomere organization and maintenance. Mutations in MYOT cause myofibrillar myopathy (MFM), a heterogeneous group of disorders characterized by focal disruption of myofibrils and accumulation of desmin, myotilin, and other proteins into inclusion bodies. While primarily considered a neuromuscular disease gene, MYOT has implications for understanding protein aggregation and cellular stress responses relevant to neurodegenerative diseases[@selcen2004].
The MYOT gene is located on chromosome 19q13.33, comprising 13 exons that encode a protein of 493 amino acids. The gene spans approximately 11.5 kilobases of genomic DNA. The promoter region contains binding sites for multiple transcription factors, including MEF2 and myoD, consistent with muscle-specific expression.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.2em;">MYOT</th></tr>
<tr><td colspan="2" style="text-align:center;font-style:italic;">Myotilin</td></tr>
<tr><th style="width:40%;">Gene Symbol</th><td><strong>MYOT</strong></td></tr>
<tr><th>Full Name</th><td>Myotilin</td></tr>
<tr><th>Chromosome</th><td>19q13.33</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/4659" target="_blank">4659</a></td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000136244</td></tr>
<tr><th>OMIM</th><td>607740</td></tr>
<tr><th>UniProt ID</th><td>Q9Y238</td></tr>
<tr><th>Protein Length</th><td>493 amino acids</td></tr>
<tr><th>Molecular Weight</th><td>57 kDa</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/myofibrillar-myopathy" style="color:#ef9a9a">Myofibrillar Myopathy</a>, <a href="/wiki/myofibrillar-myopathy" style="color:#ef9a9a">myofibrillar myopathy</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
</div>
The MYOT gene is located on chromosome 19q13.33, comprising 13 exons that encode a protein of 493 amino acids. The gene spans approximately 11.5 kilobases of genomic DNA. The promoter region contains binding sites for multiple transcription factors, including MEF2 and myoD, consistent with muscle-specific expression.
Myotilin is a 57 kDa protein localized primarily to the Z-disc of skeletal muscle sarcomeres. The protein contains an N-terminal immunoglobulin-like (Ig) domain followed by a second Ig domain in the central region, and a unique C-terminal tail. The Ig domains mediate protein-protein interactions with alpha-actinin, filamin C, and other Z-disc components. The C-terminal region contains a serine-rich domain that may be involved in post-translational modifications.
The structure of myotilin is similar to other Ig domain-containing proteins involved in cytoskeletal organization. The two Ig domains form a semi-flexible rod that can bridge between different cytoskeletal elements, providing structural stability to the sarcomere.
Myotilin is a modular protein with several distinct structural domains:
MYOT expression is restricted to skeletal and cardiac muscle. In muscle fibers, myotilin localizes precisely to the Z-disc, where it serves as a structural anchor connecting adjacent actin filaments. Expression is upregulated during muscle development and remains high in adult muscle, with some variation across different muscle fiber types.
Myotilin plays a central role in maintaining Z-disc architecture and sarcomere integrity. The protein directly binds to alpha-actinin, the primary cross-linking protein of the Z-disc, anchoring actin filaments to the Z-disc framework. This interaction is essential for the precise alignment of thin filaments and the mechanical stability of the sarcomere[@selcen2004b][@luan2020].
The protein also interacts with titin, a giant protein that spans half the sarcomere and provides elastic recoil during muscle contraction. Through these interactions, myotilin helps integrate the contractile apparatus and coordinate force transmission from sarcomeres to the muscle fiber membrane.
Beyond Z-disc function, myotilin contributes to the broader cytoskeletal network of muscle fibers. The protein links the sarcomeric cytoskeleton to the subsarcolemmal membrane through interactions with dystrophin and associated proteins. This connection is crucial for force transmission during contraction and for maintaining muscle fiber integrity.
Studies using myotilin-deficient mice have revealed that the protein is essential for normal muscle development. Knockout mice show structural abnormalities in the Z-disc and progressive muscle weakness, confirming the critical role of myotilin in sarcomere formation and maintenance[@zhou2021].
During muscle development and regeneration, myotilin plays a crucial role in sarcomere assembly. The protein is involved in the initial organization of Z-disc components and the proper alignment of actin filaments. Studies in animal models have demonstrated that myotilin is recruited to forming Z-discs early in the assembly process, where it nucleates the aggregation of other Z-disc proteins.
The assembly function of myotilin is particularly important during post-natal muscle growth and in muscle repair following injury. The protein's ability to form multimeric complexes facilitates the rapid recruitment of additional Z-disc components to the correct subcellular location.
Myofibrillar myopathy (MFM) comprises a group of genetically heterogeneous disorders characterized by focal myofibrillar destruction. MYOT mutations account for approximately 20-30% of MFM cases, representing one of the most common genetic causes of this condition. The clinical phenotype includes progressive muscle weakness, often beginning in adulthood, with distal muscle involvement in many cases.
The pathological hallmark of MFM is the presence of autophagic vacuoles and cytoplasmic inclusions containing desmin, myotilin, αB-crystallin, and other proteins. These inclusions form through mechanisms involving impaired protein degradation, oxidative stress, and mechanical damage to the Z-disc[@olive2008].
Over 50 pathogenic MYOT variants have been identified in patients with MFM. These include missense mutations, nonsense mutations, and small insertions/deletions. The majority of disease-causing mutations are located in the Ig domains, particularly the N-terminal Ig1 domain, which is critical for interactions with alpha-actinin and other binding partners[@hauser2000].
Common pathogenic variants include p.S55F, p.T57I, p.L98P, and p.A123V, all located in the Ig1 domain. These mutations disrupt protein-protein interactions and lead to protein aggregation within muscle fibers. Genotype-phenotype correlations show some variation, but generally, mutations affecting the Ig domains are associated with earlier onset and more severe disease.
The mechanism by which MYOT mutations cause protein aggregation involves both loss-of-function and toxic gain-of-function components. Mutant myotilin has impaired binding to its normal partners, leading to mislocalization and aggregation. The aggregates then sequester other proteins, including desmin and αB-crystallin, disrupting the normal cytoarchitecture.
Impaired protein quality control systems, including autophagy and the ubiquitin-proteasome system, contribute to aggregate accumulation. Studies have shown that proteasome activity is reduced in MFM muscle, while autophagy markers are increased, suggesting compensatory but insufficient clearance of damaged proteins.
MYOT mutations cause classic MFM with onset typically in adulthood (20-60 years). Patients present with progressive weakness affecting proximal and distal muscles, often beginning in the legs. Respiratory muscles may be involved in advanced disease, and cardiac involvement occurs in approximately 30% of cases.
The disease course is generally slowly progressive, with loss of ambulation occurring 10-20 years after onset in severe cases. Phenotypic variability is substantial, even among family members with the same mutation, suggesting modifier genes or environmental factors influence disease severity.
Muscle biopsy in MYOT-related MFM reveals characteristic pathological features:
Cardiac involvement in MYOT-related MFM includes cardiomyopathy and conduction defects. Dilated cardiomyopathy and left ventricular dysfunction have been reported in several families with MYOT mutations. Arrhythmias, including atrial fibrillation and heart block, may require pacemaker implantation in some patients.
The mechanism of cardiac disease likely involves disruption of the sarcomeric structure in cardiac muscle, similar to skeletal muscle. Studies in mouse models have shown that myotilin deficiency leads to cardiomyopathy, confirming the protein's essential role in cardiac muscle[@clancy2010][@schmidt2019][@christensen2017].
While primarily a genetic muscle disease, MYOT has relevance to inclusion body myositis (IBM), an age-related inflammatory myopathy. IBM shares pathological features with MFM, including protein aggregates containing myotilin and other proteins. The potential role of MYOT polymorphisms in IBM susceptibility has been explored, with recent studies identifying MYOT variants in sporadic inclusion body myositis[@janorkar2022].
The aggregation mechanisms in MFM have parallels with neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Like MFM, these disorders involve protein aggregation, impaired autophagy, and progressive cellular dysfunction. Studying MYOT mutations provides insights into general principles of protein aggregation that may inform understanding of neurodegeneration[@baroh2022].
Research has shown that myotilin aggregates in muscle fibers share features with aggregate pathology in brain diseases, including ubiquitination and sequestration of stress-responsive proteins. This suggests common cellular pathways may be involved across different protein aggregation disorders.
The primary interaction partner of myotilin is alpha-actinin, a Z-disc cross-linking protein. Myotilin binds to the central region of alpha-actinin through its Ig domains, providing a direct link between adjacent actin filaments. Mutations that disrupt this interaction impair Z-disc assembly and stability.
Myotilin interacts with filamin C, another Z-disc protein involved in cytoskeletal organization. This interaction contributes to the network of proteins maintaining sarcomere integrity. The filamin C-motilin connection is particularly important in muscle types subject to high mechanical stress.
Desmin, the intermediate filament of muscle, interacts with myotilin at the Z-disc. This interaction helps anchor the desmin network to the sarcomere. In MFM, disruption of this connection contributes to the characteristic desmin-positive inclusions.
Myotilin binds to titin, the giant elastic protein of the sarcomere. This interaction contributes to the integration of contractile elements and to the structural stability of the Z-disc region.
Gene replacement therapy using viral vectors to deliver functional MYOT is under investigation for MFM. Adeno-associated virus (AAV) vectors can deliver MYOT to muscle tissue, and studies in animal models have shown promise[@schessl2015]. Challenges include achieving adequate expression and targeting all affected muscles.
Small molecules that enhance protein folding or reduce aggregation are being explored. Compounds that promote autophagy or enhance proteasome function may help clear abnormal protein aggregates.
Current management includes physical therapy to maintain function, respiratory support for advanced disease, and cardiac monitoring with appropriate interventions. Corticosteroids and immunosuppressive agents are sometimes used but generally provide limited benefit.
Serum creatine kinase (CK) is typically normal or mildly elevated in MYOT-related MFM, limiting its utility for monitoring disease progression. Biomarker development to track disease activity and treatment response is an active area of research.
Induced pluripotent stem cells (iPSCs) from MFM patients can be differentiated into muscle cells for disease modeling and drug testing. These systems allow study of patient-specific mutations and identification of therapeutic targets.
Insights from MYOT research may inform understanding of neurodegenerative diseases. The mechanisms of protein aggregation and impaired clearance are relevant to conditions like Alzheimer's, where similar processes occur in neurons. Cross-fertilization between muscle disease and neuroscience research continues to advance understanding of both fields.
The following diagram shows the key molecular relationships involving MYOT Gene discovered through SciDEX knowledge graph analysis: